Recent performance snapshot

Cencora (COR) has seen a 2.8% decline over the past day, with the share price also lower over the past week, month, and past 3 months, even as the 1 year total return remains positive.

The recent 1 day, 1 week, and 1 month share price declines suggest momentum is fading in the short term, even though the 1 year and multi year total shareholder returns remain strong. This mix of short term weakness and longer term strength can reflect shifting views on Cencora's growth prospects and risk profile, especially with the latest share price at $325.18.

If you are assessing Cencora's recent pullback and want to see what else is moving, it can help to widen the lens with a focused stock screener such as 35 healthcare AI stocks.

With Cencora trading at $325.18 alongside an estimated intrinsic discount and a gap to analyst targets, the key question is whether the recent pullback leaves the shares undervalued or whether markets are already pricing in future growth.

Most Popular Narrative: 20.7% Undervalued

Cencora's most followed narrative puts fair value at $410.00 compared with the last close of $325.18, framing the recent share price weakness against a higher long run estimate.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

Curious what sits behind that $410.00 figure? The narrative leans on steady revenue expansion, rising margins and a richer earnings multiple than the wider US healthcare space.

Result: Fair Value of $410.00 (UNDERVALUED)

However, you still need to watch for pressure on margins from lower-fee generics and biosimilars, as well as ongoing regulatory scrutiny that could raise costs.

Another view on valuation

The narrative points to a fair value of $410.00 and labels Cencora as undervalued, but the P/E tells a tighter story. At 38.9x earnings versus a fair ratio of 37.1x, the stock screens as expensive, and it also trades richer than both peer average at 22.1x and the wider US Healthcare industry at 21.9x. The key question is whether this premium reflects a cushion of quality or a source of valuation risk if sentiment cools.

Next Steps

Given the mixed signals on valuation and sentiment, it makes sense to check the full picture for yourself and decide how comfortable you are with the trade off between upside and risk, starting with the 4 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Cencora is already on your radar, it is worth lining it up against other opportunities so you can see where the strongest risk reward trade offs sit.

• Target reliable income by scanning companies that aim to sustain higher yields with the 15 dividend fortresses.
• Spot potential bargains quickly by focusing on quality companies that appear mispriced using the 49 high quality undervalued stocks.
• Prioritize capital protection by zeroing in on resilient businesses through the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.